Guilford; F. Timothy

Patent Applications and Registrations

Patent applications and USPTO patent grants for Guilford; F. Timothy.The latest application filed is for "liposomal reduced glutathione and l-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis".

Company Profile

0.7.26

Guilford; F. Timothy - Palo Alto CA US
Guilford; F. Timothy - Palo CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, prepartion, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein Grant 8,679,530 - Guilford , et al. March 25, 2	2014-03-25
Liposomal formulation for oral administration of glutathione (reduced) Grant 8,349,359 - Guilford , et al. January 8, 2	2013-01-08
LIPOSOMAL REDUCED GLUTATHIONE AND l-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS App 20120219616 - Guilford; F. Timothy ; et al.	2012-08-30
Liposome-encapsulated glutathione for oral administration Grant 8,252,325 - Guilford , et al. August 28, 2	2012-08-28
Systemic Administration Of Nac As An Adjunct In The Treatment Of Bioterror Exposures Such As Anthrax, Virus Or Radiation And Use In Combination With Dhea For The Treatment Of Viruses App 20120141608 - GUILFORD; F. Timothy ; et al.	2012-06-07
Liposome-encapsulated Glutathione For Oral Administration App 20120135068 - Guilford; F. Timothy ; et al.	2012-05-31
Systemic Administration Of Nac As An Adjunct In The Treatment Of Bioterror Exposures Such As Smallpox And Use In Combination With Dhea For The Treatment Of Smallpox App 20120087994 - Guilford; F. Timothy ; et al.	2012-04-12
Liposome-encapsulated glutathione for oral administration Grant 8,147,869 - Guilford , et al. April 3, 2	2012-04-03
Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as smallpox and use in combination with DHEA for the treatment of smallpox Grant 8,114,913 - Guilford , et al. February 14, 2	2012-02-14
Systemic Administration Of Nac As An Adjunct In The Treatment Of Bioterror Exposures Such As Smallpox And Use In Combination With Dhea For The Treatment Of Smallpox App 20120021073 - GUILFORD; F. Timothy ; et al.	2012-01-26
Liposome-encapsulated Glutathione For Oral Administration App 20110305752 - GUILFORD; F. Timothy ; et al.	2011-12-15
Liposomally Encapsulated Reduced Glutathione, including with Other Pharmacologic Preparation, Capable of Administration as an Oral, Topical, Intraoral or Transmucosal, Prepartion, for Reversal and Prevention of Oxidation of Cholesterol and of Low Density Lipoprotein App 20110129523 - Guilford; F. Timothy ; et al.	2011-06-02
Topical Application Of Melatonin Directly Or In Liposomes For The Amelioration Of Itching And Histamine And Non-histamine Related Inflammatory Skin Changes App 20110020436 - Guilford; F. Timothy	2011-01-27
Systemic Administration Of Liposomal Reduced Glutathione For The Decorporation Of Radioactive Materials And Non-radioactive Mercury App 20100316700 - Guilford; F. Timothy	2010-12-16
Method Of Treatment Of Autism Spectrum Disorder With Liposomal Reduced Glutathione App 20100291196 - Guilford; F. Timothy	2010-11-18
Systemic Administration Of Nac As An Adjunct In The Treatment Of Terrorism Exposures Such As Radiation And For Prophylaxis App 20100233297 - Guilford; F. Timothy ; et al.	2010-09-16
Systemic Administration Of Nac For Vaccination Prophylaxis App 20100233193 - Guilford; F. Timothy ; et al.	2010-09-16
Management Of Myoclonus With Oral Liposomal Reduced Glutathione App 20100166846 - Guilford; F. Timothy	2010-07-01
Method For The Treatment Of Infection With Hhv-6 Virus And The Amelioration Of Symptoms Related To Virus Using Liposomal Encapsulation For Delivery Of Reduced Glutathione App 20090068253 - Guilford; F. Timothy	2009-03-12
Liposomal Reduced Glutathione And 1-arginine, Including With Other Ingredient(s), Capable Of Multipath Administration For Reversal And Prevention Of Obesity And For Mitochondrial Biogenesis App 20090047340 - Guilford; F. Timothy	2009-02-19
Topical Application Of Melatonin Directly Or In Liposomes For The Amelioration Of Itching And Histamine And Non Histamine Related Inflammatory Skin Changes App 20080131496 - Guilford; F. Timothy	2008-06-05
ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS App 20070077258 - Guilford; F. Timothy	2007-04-05
Liposomal Formulation For Oral Administration Of Glutathione (reduced) And/or Methylcobalamine For Diseases Related To Glutathione Deficiency And Deficiency Of The Methionine Remethylation Pathway App 20070053970 - Guilford; F. Timothy	2007-03-08
Liposomal Formulation For Oral Administration Of Glutathione (reduced) App 20060099244 - Guilford; F. Timothy	2006-05-11
Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses App 20040022873 - Guilford, F. Timothy ; et al.	2004-02-05
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor App 20030162829 - Kindness, George ; et al.	2003-08-28
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor Grant 6,534,540 - Kindness , et al. March 18, 2	2003-03-18
Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses App 20020187130 - Kindness, George ; et al.	2002-12-12
Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy App 20020182585 - Kindness, George ; et al.	2002-12-05
Inflammatory mechanism modulator composition and methods with anti-asthmatic properties App 20020137785 - Kindness, George ; et al.	2002-09-26
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor App 20020132781 - Kindness, George ; et al.	2002-09-19
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor App 20020086894 - Kindness, George ; et al.	2002-07-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.